Clinical Trial Update: Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

View source ↗

Summary

A clinical trial update indicating pomalidomide is being studied for bleeding in hereditary hemorrhagic telangiectasia in a longitudinal assessment study; the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Pomalyst (pomalidomide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT) | Status: ACTIVE_NOT_RECRUITING